Equities

Repare Therapeutics Inc

RPTX:NSQ

Repare Therapeutics Inc

Actions
  • Price (USD)3.50
  • Today's Change0.18 / 5.42%
  • Shares traded70.08k
  • 1 Year change-72.16%
  • Beta0.6999
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform6
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Repare Therapeutics Inc have a median target of 10.00, with a high estimate of 25.00 and a low estimate of 8.00. The median estimate represents a 185.71% increase from the last price of 3.50.
High614.3%25.00
Med185.7%10.00
Low128.6%8.00

Earnings history & estimates in USD

On Aug 06, 2024, Repare Therapeutics Inc reported 2nd quarter 2024 losses of -0.82 per share. This result exceeded the -0.87 consensus loss of the 7 analysts covering the company and under-performed last year's 2nd quarter results by -0.540.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate-54.80%
Repare Therapeutics Inc reported annual 2023 losses of -2.23 per share on Feb 28, 2024.
Average growth rate-51.32%
More ▼

Revenue history & estimates in USD

Repare Therapeutics Inc. had 2nd quarter 2024 revenues of 1.07m. This missed the 2.92m consensus estimate of the 7 analysts following the company. This was 81.10% below the prior year's 2nd quarter results.
Average growth rate+153.79%
Repare Therapeutics Inc. had revenues for the full year 2023 of 51.13m. This was 61.21% below the prior year's results.
Average growth rate+2,367.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.